Treace Medical Launches SuperBite and Three Other Products, Full Rollout in Q3
TMCI has more than doubled off its 52-week low of $1.17.
Summary
Treace Medical launched limited sales of four new products: SuperBite, HyperPlate XM, CartiBlaster, and GreatReleaseXM. Initial cases have been completed, and a full rollout of SuperBite is expected in Q3 2026. This follows the Q2 earnings report yesterday that showed a narrowed net loss of $15.9M on revenue of $45.4M and raised full-year guidance to $204M-$212M. The product launches represent a significant expansion of the company's portfolio, potentially accelerating revenue growth and market share gains in the bunion surgery market.
At the time of this announcement, TMCI was trading at $4.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $308.8M. The 52-week trading range was $1.17 to $7.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.